Serum vascular endothelial growth factor: a prognostic factor in cervical cancer by Petra L. M. Zusterzeel et al.
J Cancer Res Clin Oncol (2009) 135:283–290
DOI 10.1007/s00432-008-0442-y
ORIGINAL PAPER
Serum vascular endothelial growth factor: a prognostic factor 
in cervical cancer
Petra L. M. Zusterzeel · Paul N. Span · 
Marja G. K. Dijksterhuis · Chris M. G. Thomas · 
Fred C. G. J. Sweep · Leon F. A. G. Massuger 
Received: 5 February 2008 / Accepted: 16 June 2008 / Published online: 15 July 2008
©  The Author(s) 2008
Abstract
Purpose To study pre-treatment serum VEGF of patients
with invasive cervical cancer and its possible role as prog-
nostic indicator.
Methods VEGF was measured using ELISA in the largest
patient group (n = 167) to date.
Reults Serum VEGF was signiWcantly higher in advanced
tumor stage (P = 0.01), large tumor size (tumors larger than
2 cm) (P = 0.03), and the presence of vascular space inva-
sion (P = 0.05). Serum VEGF was associated with disease
free and overall survival [DFS: Hazard Ratio (HR) = 2.61;
95% CI 1.32–5.17; P = 0.006; for OS: HR = 2.09; 95% CI
1.54–2.84; P < 0.001, respectively]. In multivariate Cox
regression serum VEGF retained its prognostic value for
DFS (HR = 2.10, P = 0.03) and OS (HR = 1.92, P = 0.04).
Conclusions Serum VEGF levels correlate with more
advanced and more aggressive disease in cervical cancer
and may be a useful prognostic factor in patients with cervi-
cal cancer.
Keywords Angiogenesis · VEGF · Vascular endothelial 
growth factor · Cervical cancer · Prognostic value · Survival
Introduction
At present, results of primary surgery on one hand and
radiotherapy on the other as the primary treatment modality
in low-stage cervical carcinoma are comparable. Many
patients with cervical cancer are relatively young. In those
cases most gynecologic oncologists prefer surgery as this
preserves ovarian function and aVects sexual function to a
lesser extent than primary radiotherapy. Furthermore, sur-
gery provides information on the presence of positive
lymph nodes, which in that case leads to a worse prognosis.
The presence of positive lymph nodes will create the neces-
sity of adjuvant radiotherapy. Radiotherapy given in an
adjuvant setting leads to a high incidence of severe compli-
cations. A prognostic factor that can accurately predict
aggressive disease may identify patients with clinical stage
IB or IIA in whom radiotherapy should be considered as
primary therapy.
Angiogenesis, the formation of new blood vessels from
pre-existing capillaries, is essential for both tumor growth
and tumor spread (Folkman 1990, 1995). It seems likely
that a tumor capable of inducing an extensive angiogenic
response will show aggressive behavior and worse progno-
sis. This implies that quantifying the extent of angiogenesis
could serve as an indicator of tumor behavior and progno-
sis. Among the various angiogenic factors vascular endo-
thelial growth factor (VEGF) has a pivotal role in tumor
angiogenesis and is known to participate in neovascularisa-
tion by promoting the diVerentiation of endothelial cells
and increasing the permeability of capillaries (Ferrara
1995; Ferrara and Vis-Smyth 1997). Furthermore, tumor
associated stroma has also been shown to produce VEGF
(Fukumura et al. 1998).
The relationship between tumor or serum VEGF and
tumor behavior in cervical cancer has been the focus of a
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et al. showed that intra-tumoral protein levels of VEGF cor-
related well with local tumor progression and tumor metas-
tasis (Cheng et al. 2000). Furthermore, they found that
patients with high protein levels of VEGF had poorer dis-
ease-free and overall survival rates. Tissue expression of
VEGF was found to be signiWcantly increased in patients
with cervical intra-epithelial neoplasia compared to patients
with healthy cervices and to be highest in patients with
squamous cervical carcinoma (Dobbs et al. 1997). Some
studies showed that tumor expression of VEGF was a
highly signiWcant and independent prognostic factor in cer-
vical cancer patients treated with primary radiotherapy
(Loncaster et al. 2000). Others, however, did not Wnd tissue
VEGF expression to be of any prognostic value (Lee et al.
2002; Tjalma et al. 2000). Serum VEGF levels were signiW-
cantly higher in both patients with cervical intraepithelial
neoplasia and cervical cancer compared to healthy controls
(Lebrecht et al. 2002; Moon et al. 2000; Bachtiary et al.
2002; Mitsuhashi et al. 2005; Yang et al. 2006; Gadducci
et al. 2007). Interestingly, serum VEGF levels often
respond to successful treatment (Moon et al. 2000; Mitsuh-
ashi et al. 2005; Yang et al. 2006) and can have a prognos-
tic value (Bachtiary et al. 2002), although this was not
conWrmed in a larger study (Lebrecht et al. 2002). These
results indicate the tumor as source of elevated circulating
VEGF levels. Even so, it oVers the possibility of an easily
obtainable biomarker with possible diagnostic and prognos-
tic potential.
Currently, it is still diYcult to predict tumor behavior in
patients with cervical cancer and eVorts are being made to
Wnd prognostic factors that could contribute to customizing
patient care. The purposes of the present study were to
determine if serum concentration of VEGF is a possible
tumor marker for invasive cervical carcinoma, and to deter-
mine its role as a prognostic factor in patients with cervical
carcinoma, by correlating serum VEGF levels with estab-
lished prognostic factors and disease outcome in the largest
group of patients with cervical carcinoma so far.
Materials and methods
Patients
The Institutional Review Board of the Radboud University
Nijmegen Medical Centre approved the study. Patients
diagnosed with cervical cancer, scheduled to have an exam-
ination under anesthesia in combination with radiographic
and/or endoscopic techniques to determine tumor-stage had
their blood samples taken whilst being admitted for this
procedure. Blood samples were obtained by vena puncture
and centrifuged at 3,000£g for 10 min; serum was
aliquoted and stored at ¡20°C until further analysis. From
August 1983 until May 2000, serum samples of 167
patients were collected for testing. The case-notes of these
patients were carefully reviewed. We also determined the
serum VEGF levels in a group of 20 healthy female con-
trols, comprising blood donating volunteers. Women with
FIGO stage IB1 and IIA underwent a radical hysterectomy.
Adjuvant radiotherapy was given in case of positive lymph
nodes or positive resection areas. In women with FIGO
stage IB2, chemoradiotherapy was the treatment of choice.
Women with advanced stage disease (IIB, III and IVA)
were treated with chemoradiotherapy or radiotherapy with
hyperthermia. In the only woman with FIGO stage IVB,
treatment was only palliative. The median age of patients
was 42 years (range 20–90 years). The median duration of
follow-up was 2.8 years, ranging from 0.4 to 15.9 years.
Most patients (79%) were diagnosed with stage IB and IIA
disease and squamous cell carcinoma was the predominant
histological type. Seventy percent of the patients were pre-
menopausal. Among the patients 46% were smokers. The
control group of 20 female healthy blood-donating volun-
teers had a median age of 37 years (range 19–64; P = 0.67).
Eight of the volunteers were smokers (P = 0.71).
VEGF measurement
VEGF levels were determined in sera with a quantitative
enzyme-linked immunosorbent assay (ELISA). The details
of the assay, including those regarding speciWcity and per-
formance, have been described previously (Span et al.
2000). This assay is based on the combination of 4 poly-
clonal antibodies (Ab) raised in four diVerent animal spe-
cies including duck, chicken, rabbit and goat, which are
employed in a sandwich assay format. The assay measures
VEGF165 and VEGF121, the main isoforms of VEGF. There
is no cross-reactivity with VEGF B, VEGF C, VEGF D,
platelet derived growth factor AB (PDGF AB), insulin
growth factor type 1 (IGF-1), human growth hormone
(hGH), placental growth factor (PlGF), nerve growth factor
(NGF), tumor necrosis factor-alpha (TNF-alpha) and trans-
forming growth factor (TGF). The analytical sensitivity for
VEGF is 5 pg/ml. For VEGF, the within-run CV and
between-run CV are found to be 8.7 and 13.4%, respec-
tively.
Statistical analysis
Serum VEGF concentrations are presented as median val-
ues and expressed in g/l (interquartile range). DiVerences
in serum VEGF levels between patients and controls, and
between clinical subgroups were tested using the Mann–
Whitney U test and the Kruskal–Wallis test, where appro-
priate. Furthermore, the correlation between serum VEGF123
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were tested using Cox-univariate regression analyses. Mul-
tivariate Cox regression was performed, with only tumor
stage and VEGF entered as variables in the analysis due to
limited number of events. A two-sided P value below 0.05
was considered statistically signiWcant. The software pack-
ages SAS (version 6.12, SAS Institute Inc., Cary, NC) and
SPSS (version 12.0.1, SPSS Inc. Chicago, IL) were used
for the statistical analyses.
Results
Descriptive analyses
Table 1 summarizes descriptive data of our patient group
(n = 167). The median VEGF levels diVered signiWcantly
for patients with cervical carcinoma compared to the group
of healthy controls: 0.54 (interquartile range 0.28–1.26 g/
l) versus 0.46 g/l (interquartile range 0.29–0.60 g/l)
(P = 0.01; Table 2).
Associations of serum VEGF with clinicopathological 
characteristics
We correlated the serum VEGF levels to established prog-
nostic factors in cervical carcinoma, i.e. tumor stage, histo-
logical subtype, grade, lymph node involvement, vascular
space invasion, depth of invasion and tumor size (Table 2)
(Kristensen et al. 1999; Nguyen and Averette 1999). Serum
VEGF levels were signiWcantly higher in patients with
higher tumor stages (1.04 g/l for III and IV) as compared
to early stage tumors (0.44 g/l for IB) (P = 0.01). When
vascular space invasion was involved higher serum VEGF
levels were found as compared to cases with no vascular
space invasion (0.50 vs. 0.39 g/l, respectively; P = 0.05).
Patients with tumors larger than 2 cm also showed mark-
edly raised serum VEGF levels as compared to patients
with small tumor size (0.64 vs. 0.38 g/l, respectively;
Table 1 Clinical characteristics of patients with cervical cancer
(n = 167)
Characteristics Number (%) or (range)
Age (years) (range) 42 (20–90)

























Table 2 Serum VEGF levels in controls and diVerent clinicopatho-
logical categories of patients
VSI vascular space invasion; n number, P is for non parametric Mann–







Controls 20 0.46 0.31 0.01
Patients 167 0.54 0.98
Stage
IB 100 0.44 0.61 0.01
IIA 32 0.63 0.72
IIB 19 0.52 0.72
III/IV 16 1.04 1.28
Histology
Squamous 114 0.61 0.83 0.62
Adeno 37 0.52 0.45
Adenosquamous 14 0.55 0.53
Grade
I/II 84 0.50 0.68 0.22
III 61 0.61 0.89
Lymph nodes
Negative 102 0.51 0.61 0.67
Positive 23 0.45 1.07
VSI
No 21 0.39 0.46 0.05
Yes 81 0.50 0.73
Depth of invasion
<0.7 mm 29 0.50 0.72 0.77
¸0.7 mm 56 0.48 0.57
Tumor size
·2 cm 31 0.38 0.73 0.03
>2 cm 76 0.64 1.00123
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grade, lymph node involvement and depth of invasion. As
other factors such as age, menopausal status, smoking,
exogenous hormone use and parity might also inXuence
serum VEGF levels, we included these in our analyses.
None of these factors, however, showed statistically signiW-
cant diVerences in serum VEGF levels.
Survival analyses
Forty women (24%) showed recurrence of disease. Cox
regression analysis showed that tumor stage, positive
lymph nodes, tumor size, and serum VEGF levels were all
correlated with DFS and OS in univariate analyses
(Table 3). For VEGF, this prognostic value was signiWcant
when entered as a continuous factor (for DFS: Hazard Ratio
(HR) = 2.61; 95% CI 1.32–5.17; P = 0.006; for OS:
HR = 2.09; 95% CI 1.54–2.84; P < 0.001), precluding the
deWnition of a subjective cut-oV value, and when the
patients were dichotomized using the median value of
serum VEGF (for DFS: HR = 2.00; 95% CI 1.15–3.50;
P = 0.01; for OS: HR = 2.32; 95% CI 1.25–4.30;
P = 0.006) (shown in Fig. 1). Twenty-four women died
within 1 year after diagnosis. These patients had signiW-
cantly higher serum VEGF levels at the time of surgery
than women who survived the Wrst year [1.10 g/l (inter-
quartile range 0.38–5.36 g/l) versus 0.61 g/l (interquar-
tile range 0.21–0.1.86 g/l)] (P = 0.02).
Multivariate analysis
To assess whether the prognostic value of serum VEGF
was attributable to its strong association with tumor stage,
multivariate Cox regression analysis was performed with
tumor stage and VEGF as variables in the analysis. After
correction for tumor stage, serum VEGF retained its prog-
nostic value for both DFS (HR = 2.10, P = 0.031) and OS
(HR = 1.92, P = 0.047; Table 4).
To further characterize this prognostic value of serum
VEGF, Kaplan–Meier curves were made after stratiWcation
for tumor stage (Fig. 2). Interestingly, serum VEGF dis-
criminated between good and poor prognosis mainly in the
clinically relevant tumor stage IIA/B patients. However,
due to the low number of samples per group these analyses
were not signiWcant.
Discussion
The results of recent studies have suggested that neovascu-
larisation is one of the most important processes in tumor
growth and metastasis. VEGF induces the formation of new
Table 3 Univariate Cox regres-
sion analysis of disease free and 
overall survival
DFS OS
HR 95% CI P HR 95% CI P
Stage
IIA vs. IB 1.21 0.56–2.58 <0.001 0.94 0.38–2.33 <0.001
IIB vs. IB 2.26 1.01–5.02 3.23 1.36–7.67
III/IV vs. IB 6.50 3.20–13.2 8.05 3.80–17.1
Histology
Adeno vs. squamous 1.71 0.94–3.10 0.29 1.59 0.72–3.55 0.39
Adenosquamous vs. squamous 1.56 0.65–3.74 1.83 0.62–5.40
Grade
III vs. I/II 1.58 0.89–2.79 0.11 1.84 0.95–3.55 0.07
Lymph nodes
Positive vs. negative 1.84 1.12–3.02 0.02 8.08 1.62–40.3 0.005
VSI
Yes vs. no 1.02 0.95–1.09 0.59 2.80 0.66–11.9 0.11
Depth of invasion
¸0.7 vs. <0.7 mm 0.86 0.32–2.31 0.77 0.50 0.17–1.50 0.23
Tumor size
>2 vs. ·2 cm 4.83 1.47–15.8 0.009 5.88 1.38–24.9 0.002
Serum VEGF
Continuous (log transformed) 2.61 1.32–5.17 0.006 2.09 1.54–2.84 <0.001
Serum VEGF
>Median vs. ·median 2.00 1.15–3.50 0.010 2.32 1.25–4.30 0.006
HR Hazard ratio; vs versus; VSI 
vascular space invasion; 95% CI 
95% conWdence interval123
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show that serum VEGF levels correlate well with more
advanced disease, as levels were signiWcantly raised in
patients with higher stages of the disease, in patients with
tumors with vascular space invasion and larger tumors. Fur-
thermore, serum VEGF was an independent factor inXuenc-
ing disease-free and overall survival in our study. In a
multivariate Cox regression analysis with tumor stage and
VEGF as variables in the analysis, serum VEGF retained its
prognostic value for both DFS and OS. To further charac-
terize this prognostic value of serum VEGF, Kaplan–Meier
curves were made after stratiWcation for tumor stage
(Fig. 2). Although the number of events is too small for a
meaningful statistical analysis of the Kaplan–Meier curves
for serum VEGF in every single tumor stage, these analyses
show that the prognostic value of VEGF is particularly dis-
cernable in the clinically relevant cohort of patients with
stage IIA/B disease.
So far, the relationship between serum VEGF and tumor
behavior in cervical cancer has been the focus of a number
of studies, but the results remained equivocal (Lebrecht
et al. 2002; Moon et al. 2000; Bachtiary et al. 2002;
Mitsuhashi et al. 2005; Yang et al. 2006; Gadducci et al.
2007) (Table 5), possibly to the overall low number of
patients (n = 23–78). To our knowledge, pre-treatment
serum VEGF levels of patients with cervical carcinoma
have as yet not been reported in such a large patients group
(n = 167). Almost all studies have found that serum VEGF
levels are higher in patients when compared to controls
(Lebrecht et al. 2002; Moon et al. 2000; Mitsuhashi et al.
2005; this study; Table 5). Also, a correlation with stage is
often found (Lebrecht et al. 2002; Mitsuhashi et al. 2005;
this study). Furthermore, the correlation with tumor size we
describe here has been reported earlier (Mitsuhashi et al.
2005). However, the relationship between VEGF and recur-
rence we report here was not found by Lebrecht et al.
(2002), whereas the study of Bachtiary et al. (2002), which
also found a relation between serum VEGF and prognosis,
only entered 23 patients. This number should have been
considered too low for meaningful statistical analyses,
especially multivariate regression analysis, due to low
power and chance of spurious results. The relation between
serum VEGF and prognosis we describe here suggests that
angiogenesis may be a major mechanism in the pathogene-
sis of recurrence in cervical cancer. Previous literature
Fig. 1 Kaplan–Meier analysis of serum VEGF concentration. Dashed
line indicates < than the median, continuous line indicates ¸ than the
median. The median serum VEGF concentrations in this study popula-
tion is 0.54 g/l
Table 4 Multivariate Cox regression analysis of disease free and
overall survival
HR Hazard ratio, vs versus, 95% CI 95% conWdence interval
DFS OS
HR 95% CI P HR 95% CI P
Stage
IIA vs. IB 1.21 0.52–2.80 0.099 0.80 0.32–2.02 <0.001
IIB vs. IB 2.83 1.23–6.51 2.99 1.26–7.12




2.10 1.07–4.10 0.03 1.92 1.01–3.64 0.04123
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with prognosis and overall survival in cervical cancer
(Cheng et al. 2000; Kaku et al. 1998; Obermair et al. 1998;
Wiggins et al. 1995). Another noticeable result is that in
our study serum VEGF levels were not signiWcantly diVer-
ent between patients with squamous cell carcinoma and
Fig. 2 Kaplan–Meier curves for 
DFS (left) and OS (right) of pa-
tients dichotomized by the medi-
an level of serum VEGF after 
stratiWcation for tumor stage. 
Dashed line indicates < than the 
median, continuous line indi-
cates ¸ than the median. The 
median serum VEGF concentra-
tions in this study population is 
0.54 g/l. VEGF discriminates 
between good and poor progno-
sis mainly in tumor stage IIA/B 
patients123
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others found adenocarcinoma to be the more angiogenic
(Fujimoto et al. 1999) and aggressive subtype (Samlal et al.
1997).
As the range of serum VEGF levels in both patients and
controls is very wide, varying from 0.03 to 5.36 g/l, the
practical use of VEGF as a tumor marker in individual
patients with cervical carcinoma is limited. An explanation
for this wide range in VEGF levels might be that angiogene-
sis in oncology is a dynamic process in which there is a con-
tinuous shift of balance between tumor growth, hypoxia, and
angiogenesis, involving several inhibitors and promoters of
angiogenesis, in which VEGF plays an important role, but is
not the only determining factor. From this point of view the
serum VEGF level is probably only a snapshot impression
of this process and very susceptible to changes. Moreover,
serum VEGF levels may also vary intra-individually due to
factors such as diet and day- or night-time. Future research
should focus on further analyzing the inXuence of angiogen-
esis on tumor behavior in cervical cancer. Furthermore,
more research is needed to Wnd more about the angiogenic
switch that endothelial cells make in cancer tissue, as
healthy endothelium is mainly dormant and not susceptible
to high serum levels of VEGF (Ferrara 1995).
We conclude that serum VEGF levels are of prognostic
value in cervical carcinoma. These Wndings may lead to
future application of therapeutic trials with anti-angiogenic
factors. Moreover, its clinical use as a prognostic indicator
needs further evaluation. The FIGO classiWcation of cervi-
cal cancer, based on clinical staging, is not an accurate way
of deWning a patient’s extend of disease, leading to mis-
classiWcation in 15–25% of cases, mostly due to positive
lymph nodes, or lymph or blood vessel invasion, possibly
resulting in suboptimal care (Lagasse et al. 1980). Patients
with positive lymph nodes or lymph or blood vessel invasion
need adjuvant radiotherapy leading to a high incidence of
complications. Determination of pre-treatment serum
VEGF levels may help to improve the selection of the most
appropriate therapy regime for an individual patient with
low-stage cervical cancer. Perhaps even better might be the
combination of VEGF with other markers for lymphogenic
of vascular spread of disease in low-stage cervical cancer,
such as squamous cell carcinoma antigen (SCC) and CA-
125 serum levels (Massuger et al. 1997).
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